Viatris Inc.

What does Viatris own?
Viatris owns the Lipitor, Viagra, Xanax, and Eliquis brands, along with a portfolio of over 1,400 approved generic molecules across cardiovascular, respiratory, central nervous system, oncology, immunology, and other therapeutic areas. The company also has a pipeline of complex generics and biosimilars. Its product portfolio was formed through the merger of Upjohn (Pfizer's legacy brand-name drug business) and Mylan (a global generic pharmaceutical company).

Is Viatris publicly traded?
Yes, Viatris Inc. is publicly traded on the Nasdaq stock exchange under ticker VTRS. The company has a dispersed shareholder base with institutional investors holding the majority of shares. Pfizer distributed its Viatris shares to Pfizer shareholders in 2021 and no longer holds a significant ownership stake. Viatris returned more than $1 billion to shareholders in 2025 through share repurchases and dividends.

Who founded Viatris?
Viatris was not founded by individuals. It was created in November 2020 through the merger of Upjohn, a division of Pfizer that held legacy brand-name drugs, and Mylan, a global generic pharmaceutical company founded in 1961 in White Sulphur Springs, West Virginia. The merger combined Upjohn's brand-name portfolio with Mylan's generic manufacturing capabilities to form a new company focused on providing access to affordable medicines.

Where is Viatris headquartered?
Viatris is headquartered in Canonsburg, Pennsylvania, USA. The company maintains its corporate offices in Pennsylvania and operates manufacturing facilities, distribution centers, and sales offices across the world. Its manufacturing network includes facilities in the United States, India, Europe, and China.

How many brands does Viatris own?
Viatris owns four key brand-name medicines: Lipitor, Viagra, Xanax, and Eliquis. The company also owns a portfolio of over 1,400 approved generic molecules across multiple therapeutic areas. In 2025, the company generated approximately $324 million in new product revenues and expects $450 million to $550 million in new product revenues in 2026 from its pipeline of generic and complex generic products.

Who owns Viatris?
Viatris is a publicly traded company with a dispersed shareholder base. Institutional investors, including mutual funds and investment firms, hold the majority of shares. No single shareholder has controlling ownership. Pfizer, the former parent of Upjohn, distributed its Viatris shares to Pfizer shareholders in 2021 and no longer holds a significant stake. The company is governed by a board of directors with independent representation.

What are Viatris's largest brands?
Lipitor and Viagra are Viatris's most recognizable brand-name products. Lipitor is a cholesterol-lowering statin medication originally developed by Pfizer. Viagra is an erectile dysfunction medication also originally developed by Pfizer. Xanax, an anti-anxiety medication, and Eliquis, an anticoagulant, are the company's other major brand-name products. Together, these brands contribute to the Developed Markets segment, which generated $8.5 billion in revenue in 2025.

Viatris was formed in November 2020 through the merger of Upjohn and Mylan. The deal was announced in July 2019 and completed approximately 16 months later. The combined company was named Viatris, derived from the Latin words "via" (path) and "tris" (three), representing the company's stated pillars of access, innovation, and reliability.

Upjohn was a division of Pfizer that held the company's legacy brand-name drugs, including Lipitor (cholesterol), Viagra (erectile dysfunction), and Xanax (anxiety). Pfizer spun off Upjohn as part of a broader strategy to separate its growth-oriented businesses from its established products. The spin-off allowed Pfizer to focus on innovative drugs while giving Upjohn's legacy products a new corporate home.

Mylan was a global generic pharmaceutical company founded in 1961 in White Sulphur Springs, West Virginia. By the time of the merger, Mylan had grown into one of the world's largest generic drug manufacturers, with a portfolio of approximately 1,400 approved molecules and manufacturing operations in multiple countries. Mylan had faced its own controversies, including a public backlash over the pricing of its EpiPen product in 2016.

The merger created a company with approximately $19 billion in combined revenue at formation, though revenue has since declined due to divestitures, generic competition, and manufacturing challenges. Pfizer received shares in the new company as part of the transaction but distributed those shares to Pfizer shareholders in 2021, severing the ownership connection between the two companies.

Following the merger, Viatris focused on integrating the two businesses and optimizing its portfolio. The company divested non-core assets, including its biosimilars business, which it sold to Biocon Biologics in a transaction completed in 2023. Viatris also sold its over-the-counter business in certain markets and streamlined its manufacturing network.

In late 2024, the U.S. Food and Drug Administration issued a warning letter and import alert for Viatris's oral finished dose manufacturing facility in Indore, India. The FDA banned 11 generic drugs from being imported into the United States from the facility. The import alert and supply disruptions at Indore cost Viatris approximately $370 million in lost revenue in 2025. The company reported in early 2026 that it had substantially completed remediation at the facility and was awaiting FDA reinspection.

In February 2025, a fire broke out at Viatris's oral solid dose manufacturing facility in Nashik, India, causing a temporary halt in production. The company expected the Nashik facility to resume operations within approximately two months.

In 2025, Viatris initiated an enterprise-wide strategic review to restructure its operations. The results, announced in February 2026, included a planned global workforce reduction of up to 10 percent over three years, with total restructuring charges of $700 million to $850 million. The company expects $600 million to $700 million in annual cost savings once the restructuring is complete, with approximately $400 million in net savings after reinvestment.

For the first quarter of 2026, Viatris reported total revenues of $3.5 billion, up 8 percent on a reported basis and 3 percent operationally compared to the first quarter of 2025. Growth was driven primarily by Greater China, where revenues increased 22 percent. The company reaffirmed its 2026 financial guidance, expecting total revenue growth of approximately 3 percent.

Viatris publishes an annual sustainability report and has stated commitments to environmental responsibility, access to healthcare, and ethical supply chain management. The company is not a Certified B Corporation.

On access to medicine, Viatris reports that it provides affordable medicines to patients in over 165 countries. The company's generic drug portfolio is its primary contribution to healthcare access, as generic drugs are typically priced 80 to 90 percent below their brand-name equivalents. Viatris also has patient access programs in certain markets.

On environmental commitments, Viatris has set targets for reducing greenhouse gas emissions from its manufacturing operations. The company operates manufacturing facilities in the United States, India, Europe, and China, and these facilities are subject to environmental regulations in their respective jurisdictions. Viatris reports on its environmental performance through its annual sustainability report.

On supply chain ethics, Viatris requires suppliers to comply with its Code of Conduct, which covers labor standards, human rights, anti-corruption, and environmental practices. The company conducts supplier audits through third-party verifiers.

The company's manufacturing challenges in India, including the FDA warning letter for the Indore facility and the fire at the Nashik facility, have raised questions about its supply chain reliability and manufacturing quality controls. Viatris has reported that it has substantially completed remediation at Indore and is awaiting FDA reinspection.

Viatris has faced significant regulatory and manufacturing challenges at its Indian production facilities. In late 2024, the FDA issued a warning letter and import alert for the company's oral finished dose manufacturing facility in Indore, India. The FDA banned 11 generic drugs from being imported into the United States from the facility. The warning letter cited issues with written procedures, anomalies in chemical reports, and failure to properly investigate drug discrepancies. The Indore supply disruption cost Viatris approximately $370 million in lost revenue in 2025. The company reported in early 2026 that it had substantially completed remediation and was awaiting FDA reinspection.

In February 2025, a fire broke out at Viatris's oral solid dose manufacturing facility in Nashik, India. Production was temporarily halted. The company expected the facility to resume operations within approximately two months.

The company's predecessor, Mylan, faced a significant public controversy in 2016 over the pricing of its EpiPen product. Mylan raised the price of EpiPen by approximately 400 percent over several years, drawing criticism from politicians, patient advocacy groups, and the media. Mylan settled with the U.S. Department of Justice for $465 million in 2017 over allegations that it misclassified EpiPen as a generic drug to avoid paying higher rebates to Medicaid.

In 2025, Viatris reported a U.S. GAAP net loss of $3.5 billion, driven primarily by a non-cash goodwill impairment charge of $2.9 billion recorded in the first quarter. The impairment reflected a reduction in the carrying value of goodwill on the company's balance sheet, indicating that the market value of certain acquired assets had declined below their book value.